Biotech · Private company
Azafaros B.V.
Track this companyFree. Adds Azafaros B.V. to your Dealase workspace and tells you when its record changes.
Clinical trials43 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- AZ-3102Phase 3 · Gangliosidoses, GM2ClinicalTrials.gov · fetched Nov 12, 2026
- AZ-3102Phase 3 · Niemann-Pick Type C DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- NizubaglustatPhase 3 · Niemann-Pick Type C DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)PHASE3 · RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT07082725 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisPHASE3 · RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT07054515 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 GangliosidosisPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 30, 2025ClinicalTrials.gov NCT07082543 · fetched Nov 12, 2026
- GM1 and GM2 Gangliosidosis PROspective Neurological Disease TrajectOry Study (PRONTO)COMPLETED · started Feb 22, 2022ClinicalTrials.gov NCT05109793 · fetched Nov 12, 2026